慢性肝病人群接种新型冠状病毒疫苗相关研究进展

摘要/Abstract

摘要： 新型冠状病毒肺炎因其较高的传播率和人群普遍易感性给社会造成了巨大影响。目前,各国都提倡接种新型冠状病毒疫苗以产生群体免疫来抵御新冠肺炎疫情。我国现存超3亿的慢性肝病患者,有研究表明慢性肝病人群相比于健康人群面临着更高的感染风险,而接种疫苗能够有效降低患者的重症化率。然而,关于这一特殊人群接种新冠疫苗的数据有限,本文将围绕慢性肝病人群接种新冠疫苗安全性和有效性的研究进展进行综述,以期更好地为这一特殊人群新冠疫苗接种提供参考。

毛玉锋, 乔菲, 薛勤, 李元元, 王福生. 慢性肝病人群接种新型冠状病毒疫苗相关研究进展[J]. 肝脏, 2022, 27(8): 935-939.

参考文献

[1] COVID-19 Dashboard [https://coronavirus.jhu.edu/map.html]
[2] COVID-19 vaccine tracker and landscape [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines]
[3] Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet,2021, 396:1979-1993.
[4] Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, 21:1645-1653.
[5] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology, 2014, 60:2099-2108.
[6] Qi X, Liu Y, Wang J, et al.Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut,2021, 70:433-436.
[7] Goes LR, Siqueira JD, Garrido MM, et al.New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil. Infect Genet Evol, 2021, 94:104998.
[8] Zhang C, Shi L, Wang FS: Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol,2020, 5:428-430.
[9] McGrowder DA, Miller F, Anderson Cross M, et al. Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. Diseases,2021,9:50.
[10] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA,2020, 323:1061-1069.
[11] Sharma A, Patnaik I, Kumar A, et al.COVID-19 Vaccines in Patients With Chronic Liver Disease. J Clin Exp Hepatol, 2021, 11:720-726.
[12] Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 2020, 382:1708-1720.
[13] Liu H, He X, Wang Y, et al. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. Hepatol Int, 2020, 14:432-436.
[14] Qin J, Wang H, Qin X, et al. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. Hepatology, 2020, 72:1491-1493.
[15] Dale M, Sogawa H, Seyedsaadat SM, et al.Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients. Transplant Proc, 2021, 53:1175-1179.
[16] Wang J, Hou Z, Liu J, et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study. J Hepatol, 2021, 75:439-441.
[17] Xiang T, Liang B, Wang H, et al.Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection. Cell Mol Immunol, 2021,18:2679-2681.
[18] He T, Zhou Y, Xu P, et al. Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection. Liver Int, 2022, 10.1111
[19] Thuluvath PJ, Robarts P, Chauhan M.Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol, 2021, 75:1434-1439.
[20] Ai J, Wang J, Liu D, et al. Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases (CHESS-NMCID 2101): A multicenter study. Clin Gastroenterol Hepatol, 2021,S1542-3565:01346-X.
[21] Limited HHMG: Antibody Response to COVID-19 Vaccines in Liver Disease Patients. 2021.
[22] Limited HHMG: A Study to Evaluate Vaccines Against COVID-19 in the Real World. 2021.
[23] Institute of Liver and Biliary Sciences I: Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis. 2021.
[24] Province HSIoG: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101). 2021.
[25] Hospital D: Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication (Nor-vaC). 2021.
[26] University TSAHoCM: Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases (SIMPLE). 2021.
[27] Hospital B: COVID-19 Vaccines in Patients With Chronic Liver Disease. 2021.
[28] Research PIoMEa: Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease (EvaLongCovid). 2021.
[29] Cornberg M, Buti M, Eberhardt CS, et al. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol, 2021, 74:944-951.
[30] 国家卫生健康委员会: 新冠病毒疫苗接种技术指南(第一版).传染病信息 2021,34:97-98.
[31] 中华医学会感染病学分会, 中华医学会风湿病学分会,特殊人群(慢性肝病、结核病和风湿免疫病患者)新型冠状病毒疫苗接种专家建议. 中华传染病杂志,2021, 39:398-403.
[32] Fix OK, Blumberg EA, Chang KM, et al.American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology,2021, 74:1049-1064.